Edition:
India

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

0.57USD
18 Apr 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.57
Open
$0.57
Day's High
$0.58
Day's Low
$0.57
Volume
69,688
Avg. Vol
109,210
52-wk High
$2.49
52-wk Low
$0.48

Summary

Name Age Since Current Position

David Hoffmann

70 2018 Chairman of the Board

James Brown

58 1998 President, Chief Executive Officer and Director

Michael Arenberg

49 2018 Chief Financial Officer

Judy Joice

58 2014 Senior Vice President - Operations and Corporate Quality Assurance

Myriam Theeuwes

2017 Senior Vice President - Clinical Development

Simon Benito

73 2005 Independent Director

Terrence Blaschke

72 2006 Independent Director

Armand Neukermans

74 2001 Independent Director

Jon Saxe

82 2003 Independent Director

Biographies

Name Description

David Hoffmann

Mr. David R. Hoffmann is an Chairman of the Board of the Company effective December 31, 2018. Mr. Hoffmann served as a Director of DURECT since December 2002 and as Lead Independent Director since December 2010. He had a distinguished career at ALZA Corporation (now a Johnson & Johnson company) from 1976 to 2002, where he held roles of increasing responsibility, including serving as Vice President and Treasurer for 10 years until his retirement inOctober 2002. Mr. Hoffmann is currently a member of the Board of Directors and Chairman of the Audit Committee of Molecular Templates, an oncology company. He holds a B.S. in Business Administration from the University of Colorado.

James Brown

Dr. James E. Brown, DVM., is President, Chief Executive Officer and Director of DURECT Corporation. He co-founded DURECT in February 1998 and has served as our President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995, and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology. Dr. Brown’s scientific expertise and pharmaceutical industry experience as well as the valuable perspective as the Company’s Chief Executive Officer and co-founder into the management, strategies and operations of the Company are among the special qualifications that he brings to his service as a Director of the Company.

Michael Arenberg

Mr. Michael H. Arenberg, J.D. is Chief Financial Officer of the Company. Since joining the Company in 1999, Mr. Arenberg has held a variety of positions with increasing responsibilities in general management, sales & marketing and business development. Prior to joining the Company, in 1996, Mr. Arenberg co-founded IntraEAR, Inc., a drug delivery medical device company, where he served as Vice President of Sales, Marketing and Business Development until its acquisition by the Company in 1999. Mr. Arenberg holds an M.B.A. from the Leavey School of Business at Santa Clara University and a J.D. from the University of Denver

Judy Joice

Ms. Judy R. Joice is Senior Vice President - Operations and Corporate Quality Assurance of DURECT CORPORATION. Previously, Ms. Joice served as our Vice President, Corporate Quality Assurance since July 2008 and as our Executive Director, Quality Assurance from July 2007 to July 2008. She has over 25 years’ experience in the pharmaceutical industry with such companies as Nektar Therapeutics, Oread, Roche Pharmaceuticals, and Syntex Research. During her career, Ms. Joice has gained broad experience in CMC development activities including novel excipients, new chemical entities, devices, and combination products. She has developed, implemented and managed all aspects of company-wide quality systems and compliance functions, ranging from drug development through commercial manufacturing. Ms. Joice has a B.S. in Chemistry from California State University, Hayward.

Myriam Theeuwes

Ms. Myriam Theeuwes is Senior Vice President - Clinical Development of the company. She joins DURECT from Johnson & Johnson where she spent 18 years, most recently as Compound Development Team Leader for Janssen Pharmaceutical's global public health initiatives where she led the development and launch of products including SIRTURO (bedaquiline), the first drug with a new mechanism of action to treat tuberculosis in over 40 years. Since its original FDA approval in 2012, the product has been widely registered in high burden areas and is available in over 100 countries globally. Prior to joining Janssen, Dr. Theeuwes spent 11 years at ALZA Corporation in positions of increasing responsibility culminating in her appointment as General Manager and Associate Medical Director for Europe. Before her career in industry, Dr. Theeuwes was a practicing resident dentist at theUniversity of California San Francisco(UCSF) and San Marcos Health Center in Honduras. She received her dental degree from the University of Leuven,Belgiumand obtained herCaliforniastate dental license after completing the Advanced General Dentistry Residency Program at UCSF.

Simon Benito

Mr. Simon X. Benito is an Independent Director of DURECT Corporation, since April 2005. Mr. Benito is currently a director and chairman of the Audit Committee of Inovio Pharmaceuticals Corporation, a biomedical company. From 1974 to 1999, Mr. Benito held various positions at Merck & Co Inc. including Senior Vice President, Vaccine Division from 1996 to 1999, Executive Vice President, Merck-Medco Managed Care from 1994 to 1996 and Executive Director and Vice President, Merck Human Health, Japan from 1986-1993. Mr. Benito was a Fellow of the Institute of Chartered Accountants in England and Wales from 1969 to 1999 until his retirement from Merck. Mr. Benito’s pharmaceutical industry experience as relates to executive management, corporate transactions and international operations as well as his financial and accounting expertise are among the qualifications he brings to the Board and his service as a Director of the Company.

Terrence Blaschke

Dr. Terrence F. Blaschke, M.D., is an Independent Director of DURECT Corporation, since December 2006. Dr. Blaschke has served on the faculty of Stanford University since 1974 and is Professor of Medicine and Molecular Pharmacology (Emeritus) at the Stanford University School of Medicine. He is currently a senior program officer, Global Health Discovery and Translational Science at the Bill and Melinda Gates Foundation. Dr. Blaschke held the position of Vice President of Methodology and Science at Pharsight Corporation from 2000 to 2002. Dr. Blaschke has served as an independent consultant working with a number of leading pharmaceutical and biotechnology companies. Dr. Blaschke was formerly a board member of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals, two publicly-traded companies. He has also worked as a special government employee for the U.S. Food and Drug Administration (“FDA”) and has served as the chairman of the FDA’s Generic Drugs Advisory Committee. Dr. Blaschke’s medical and scientific expertise and pharmaceutical industry experience as relates to drug development are among the qualifications he brings to the Board and his service as a Director of the Company.

Armand Neukermans

Dr. Armand P. Neukermans, Ph.D., is an Independent Director of DURECT Corporation, since March 2001. Dr. Neukermans founded Xros, Inc. in December 1996. Xros was acquired by and became a division of Nortel Networks in March 2000. Throughout and until June 2002, Dr. Neukermans held the position of Chairman and Chief Technical Officer at Xros. In October 1993, Dr. Neukermans founded Adagio Associates, a consulting firm in the area of instrumentation, metrology and microfabrication and currently serves as its President. From 1992 to 1993, Dr. Neukermans was Vice President, Systems Development at Teknekron TSDC. Between 1985 and 1992, Dr. Neukermans held various positions at Tencor Instruments including Vice President and Chief Technical Officer. From 1973 to 1985, Dr. Neukermans held various positions at Hewlett Packard Company, HP Labs, including Department Manager. Dr. Neukermans holds an Engineer’s Degree in Mechanical and Electrical Engineering from Louvain University, an M.S. in Electrical Engineering from Arizona State University and a Ph.D. in Applied Physics from Stanford University. Dr. Neukermans was named Silicon Valley Inventor of the Year in 2001. Dr. Neukerman’s engineering and technical expertise and general industrial experience as relates to executive management and business operations are among the qualifications he brings to the Board and his service as a Director of the Company.

Jon Saxe

Mr. Jon S. Saxe, Esq., J.D., is Independent Director of DURECT Corporation., since September 2003. Mr. Saxe is currently a director of a number of biotechnology and pharmaceutical companies including SciClone, VistaGen and several private companies. From January 1995 to May 1999, Mr. Saxe was President of Protein Design Labs. During 1999, he was an Executive-in-Residence at Institutional Venture Partners, a venture capital firm. Mr. Saxe was President of Saxe Associates, a biotechnology and pharmaceutical consulting firm, from May 1993 to December 1994. He served as President, Chief Executive Officer and as a director of Synergen, Inc., a biopharmaceutical company acquired by Amgen from October 1989 to April 1993. From August 1984 through September 1989, Mr. Saxe was Vice President, Licensing and Corporate Development at Hoffmann-LaRoche and also head of the patent law department and Associate General Counsel at the company from September 1978 through September 1989. Mr. Saxe received his B.S. in Chemical Engineering from Carnegie-Mellon University, a J.D. from George Washington University School of Law and an LL.M. from New York University School of Law.

Basic Compensation